Bayer Secures €3 Billion Apollo Investment for LARC Business
LEVERKUSEN, Germany, July 10, 2026 Bayer AG has announced a landmark €3.0 billion equity investment agreement with global asset...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
LEVERKUSEN, Germany, July 10, 2026 Bayer AG has announced a landmark €3.0 billion equity investment agreement with global asset...
Cambridge, UK & Wilmington, Delaware, December 2025 — AstraZeneca has announced that the U.S. Food and Drug Administration has...
Taipei, Taiwan, December 2025 — Formosa Pharmaceuticals has announced a licensing agreement with Rxilient Biotech to commercialize clobetasol propionate...
Sydney, Australia, December 3, 2025 — Kazia Therapeutics has announced the pricing of a US $50 million private placement...
